

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT

OVERSEAS PROGRESS OF TAVI BUSINESS

This announcement is made by MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the Company’s shareholders and potential investors of the latest business developments of the Group.

The board of directors (the “**Director(s)**”) of the Company (the “**Board**”) is pleased to announce that, as of the date of this announcement, the Group’s VitaFlow® series transcatheter aortic valve implantation (“**TAVI**”) systems have been introduced into 35 countries and regions globally, with a cumulative implantation volume of nearly 1,300 cases. Among these, the implantation volume for 2025 is expected to exceed 850 cases, representing a year-on-year increase of nearly 350%. In the second half of 2025, driven by the continued expansion of VitaFlow Liberty® following its CE mark approval in European countries and increasing market share in emerging markets in Asia and Latin America, the implantation volume increased by more than 170% compared to the first half of the year.

The Board believes that the recent acquisition of MicroPort Cardiac Rhythm Management Limited will further strengthen the Group's local channel resources and clinical support systems in mature markets such as Europe, significantly enhancing the market access efficiency for TAVI products and the penetration depth in existing markets. Looking ahead, the Group will continue to leverage integration synergies, advance the development of next-generation TAVI products, strengthen its integrated structural heart disease solutions, and enhance its overall competitiveness in the global valve therapy landscape.

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, December 30, 2025

As at the date of this announcement, the executive Directors are Mr. Zhang Ruinian and Mr. Philippe Wanstok, the non-executive Directors are Mr. Chen Guoming, Dr. Brian Chang, Mr. Deng Aoyi and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang and Dr. Hu Bingshan.